Key result
Overweight and obesity linked to significantly reduced glucose effectiveness versus lean individuals.
Why the study?
Obesity is known to impair insulin sensitivity, but its effect on the insulin-independent component of glucose tolerance, glucose effectiveness, is less studied.
Does increasing body mass index affect glucose effectiveness and its components?
Cross-Sectional (n=204)
Does increasing body mass index affect glucose effectiveness and its components?
Effect estimate: r = -0.3
Absolute Event Rate: 1.84% vs 2.38%
p-value: p=<0.0001
Glucose effectiveness deteriorates in overweight individuals compared to lean individuals, but does not worsen further with increasing obesity.
Background Obesity is known to induce a deterioration of insulin sensitivity (SI), one of the insulin‐dependent components of glucose tolerance. However, few studies investigated whether obesity affects also the insulin‐independent component, that is glucose effectiveness (SG). This cross‐sectional study aimed to analyse SG and its components in different body mass index (BMI) categories. Materials and methods Three groups of subjects spanning different BMI (kg m−2) categories underwent a 3‐h frequently sampled intravenous glucose tolerance test: Lean (LE; 18.5 ≤ BMI < 25, n = 73), Overweight (OW; 25 ≤ BMI < 30, n = 90), and Obese (OB; BMI ≥ 30, n = 41). OB has been further divided into two subgroups, namely Obese I (OB‐I; 30 ≤ BMI < 35, n = 27) and Morbidly Obese (OB‐M; BMI ≥ 35, n = 14). Minimal model analysis provided SG and its components at zero (GEZI) and at basal (BIE) insulin. Results Values for SG were 1.98 ± 1.30 × 10−2·min−1 in all subjects grouped and 2.38 ± 1.23, 1.84 ± 0.82, 1.59 ± 0.61 10−2·min−1 in LE, OW and OB, respectively. In all subjects grouped, a significant inverse linear correlation was found between the log‐transformed values of SG and BMI (r = −0.3, P < 0.0001). SG was significantly reduced in OW and OB with respect to LE (P < 0.001) but no significant difference was detected between OB and OW (P = 0.35) and between OB‐I and OB‐M (P = 0.25). Similar results were found for GEZI. BIE was not significantly different among NW, OW and OB (P = 0.11) and between OB‐I and OB‐M (P ≥ 0.07). Conclusions SG and its major component GEZI deteriorate in overweight individuals compared to those in the normal BMI range, without further deterioration when BMI increases above 30 kg m−2.
No takes yet. Share an insight, caveat, or question.
Morettini et al. (2019) conducted a cross-sectional in Obesity (n=204). Overweight and Obesity (BMI ≥ 25) vs. Lean (18.5 ≤ BMI < 25) was evaluated on Glucose effectiveness (SG) (r = -0.3, p=<0.0001). Overweight and obesity were associated with significantly reduced glucose effectiveness compared to lean individuals (1.84 and 1.59 vs 2.38 x 10^-2 min^-1; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: